Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide injection activates GLP-1 receptors in the brain to reduce appetite and regulate blood sugar, producing weight loss in the majority of users. Clinical trials published in major medical journals document average reductions of 10–22% of starting body weight, though individual outcomes vary significantly based on genetics, lifestyle, and treatment duration. Understanding realistic expectations helps patients make informed decisions about whether semaglutide aligns with their health goals.

Clinical Trial Data on Semaglutide Weight Loss

The STEP trials, which enrolled over 4,500 adults with overweight or obesity, documented semaglutide's weight reduction profile across 68 weeks of treatment. In STEP 1, participants receiving the highest dose lost an average of 15.3% of body weight compared to 2.6% in the placebo group. STEP 2 extended findings to participants with established cardiovascular disease, showing similar efficacy and sustained weight reduction through a maintenance phase.

Dose escalation influences magnitude of weight loss, with higher maintenance doses producing greater average reductions than lower doses. Most patients begin on a lower introductory dose to minimize gastrointestinal side effects, then titrate upward every four weeks until reaching their target maintenance dose. Peak weight loss typically occurs between weeks 40 and 68 of continuous treatment, after which losses often stabilize or gradually increase depending on adherence and lifestyle factors.

Real-world outcomes in clinical practice settings reflect trial data but show wider variation than controlled research environments. Observational studies of patients receiving compounded semaglutide report average weight reductions of 8–18% of body weight over six months to one year, with some individuals achieving losses exceeding 25% of starting weight. This variability underscores the importance of personalized assessment and genetic insights to predict individual response likelihood.

Factors That Influence Individual Semaglutide Weight Loss Results

Genetic variation in GLP-1 receptor sensitivity, determined by specific alleles such as rs6923761, significantly affects how efficiently semaglutide produces appetite suppression and weight reduction. Individuals with genetic variants associated with heightened GLP1R expression often achieve more pronounced weight loss at lower doses, while those with reduced receptor activity may require higher doses or longer treatment duration to reach comparable results. PlexusDx Precision Peptide Genetic Test identifies these pathways through analysis of 14 metabolic systems and 49 peptides to predict treatment responsiveness before initiating therapy.

Baseline metabolic rate, body composition, and insulin resistance status interact with semaglutide's mechanism to determine net weight loss trajectory. Patients with elevated fasting insulin levels often experience accelerated initial weight reduction because semaglutide simultaneously improves insulin sensitivity and reduces food intake. Conversely, individuals with very low metabolic rates may lose weight more gradually despite optimal adherence, necessitating adjustment of expectations and potentially longer treatment windows to achieve health goals.

Lifestyle integration—including consistent physical activity, dietary composition, and sleep quality—acts synergistically with semaglutide to enhance weight loss outcomes. Patients who maintain regular exercise and prioritize protein intake while taking semaglutide typically achieve 20–30% greater weight reductions than those who rely on medication alone. Treatment success depends on viewing semaglutide as one component of comprehensive metabolic management rather than as a standalone intervention.

Timeline and Expected Weight Loss Progression on Semaglutide

Most patients begin noticing appetite reduction and modest weight loss within the first two to four weeks of starting semaglutide, though this early phase often reflects water loss and reduced carbohydrate intake rather than fat tissue reduction. By weeks 8–12, fat mass loss becomes measurable as appetite suppression deepens and caloric deficit accumulates. The most substantial weight reduction typically occurs between weeks 16 and 32 of continuous treatment, with rates averaging 0.5–1.5 pounds per week during this acceleration phase.

Weight loss velocity often slows between weeks 40 and 68 as the body adapts to reduced caloric intake and hormonal changes stabilize, a phenomenon known as weight loss plateau. This slowdown is physiologically normal and does not indicate treatment failure; it reflects the body's homeostatic mechanisms attempting to maintain energy balance. Some patients maintain steady gradual loss throughout treatment, while others experience periods of stable weight interrupted by subsequent reductions during dosage adjustments.

Discontinuation of semaglutide without concurrent lifestyle modification typically results in gradual weight regain over 6–12 months, though patients usually do not return to their complete pre-treatment weight. Studies suggest approximately 50–60% of weight loss persists one year after stopping semaglutide in patients who maintain improved dietary habits. Extended treatment duration or transition to alternate GLP-1 agents allows sustained weight reduction and metabolic benefits for individuals whose goals require long-term management.

PlexusDx Compounded Semaglutide: Personalized Dosing Without Price Escalation

PlexusDx delivers pharmaceutical-grade compounded semaglutide injection from licensed 503A compounding pharmacies to all 50 states without insurance requirements or membership fees. Treatment begins at $149 per month regardless of starting dose, with flexibility to adjust injection volume and frequency based on individual response and provider recommendation. The PlexusDx pricing model ensures that patients do not face escalating monthly costs as their therapeutic dose increases—a transparent alternative to branded medication structures that charge per-dose increments.

Precision Peptide Genetic Test adds an optional layer of personalization by identifying genetic markers across GLP1R, GIPR, FTO, MC4R, and 10 additional peptide pathways that predict semaglutide responsiveness and optimal dosing strategy. Available for $99 as an add-on after the first month of treatment, this test maps 14 metabolic systems and 150+ genetic insights to guide providers in tailoring dose escalation timelines and selecting between semaglutide, tirzepatide, or combination therapy. Patients achieving access to this genetic roadmap often experience faster time-to-efficacy and reduced trial-and-error adjustments compared to standard empirical dosing.

PlexusDx semaglutide qualifies for HSA and FSA account funding, reducing net medication cost for eligible patients by 20–35% depending on tax bracket and account type. Direct-to-patient access eliminates pharmacy markup layers typical of retail dispensing, allowing PlexusDx to maintain competitive pricing while maintaining clinical-grade compounding standards. This model prioritizes sustained adherence and weight loss success by removing financial barriers that often interrupt treatment during critical dose-adjustment phases.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How much weight can I realistically expect to lose on semaglutide in three months?

Clinical data suggests average weight reduction of 4–8 pounds in the first month, with acceleration to 8–15 pounds total by month three as your dose reaches target maintenance level. Individual results vary widely based on genetic response factors, baseline metabolism, and lifestyle adherence. PlexusDx Precision Peptide Genetic Test can help your provider predict your likely response trajectory before starting treatment.

Why do some people lose 25% of body weight on semaglutide while others lose only 10%?

Genetic variation in GLP-1 receptor sensitivity, insulin resistance severity, baseline metabolic rate, and lifestyle integration all significantly influence weight loss magnitude. The STEP trials documented 15–20% average reductions, but participants ranged from 5% to 35% loss depending on these individual factors. PlexusDx identifies key genetic variants such as GLP1R rs6923761 and FTO rs9939609 that predict your personalized response potential.

Will my PlexusDx monthly cost increase as my semaglutide dose goes up?

No. PlexusDx compounded semaglutide injection starts at $149 per month and remains at that flat rate regardless of dose adjustments—your dose may need to go up, but your price won't. This transparent pricing model ensures cost stability while your provider optimizes your therapeutic dosage for maximum weight loss and tolerability.

What happens to my weight after I stop taking semaglutide?

Research shows approximately 50–60% of weight loss persists one year after discontinuation in patients who maintain improved eating habits, though gradual regain is common without ongoing treatment or lifestyle support. Many patients benefit from extended treatment duration or transition to maintenance dosing rather than complete discontinuation. Discuss long-term management strategies with your PlexusDx provider to sustain metabolic improvements.

Can the Precision Peptide Genetic Test predict if semaglutide will work well for me?

Yes. The $99 Precision Peptide Genetic Test analyzes GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, MC4R rs17782313, and 46 additional peptides across 14 metabolic pathways to predict your genetic response capacity to semaglutide, tirzepatide, or combination therapy. Available as an add-on after your first treatment month, these 150+ genetic insights help your provider customize dose escalation and therapy selection for faster efficacy.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves